Peter Nash
YOU?
Author Swipe
View article: Author Correction: Engineering novel CRISPRi repressors for highly efficient mammalian gene regulation
Author Correction: Engineering novel CRISPRi repressors for highly efficient mammalian gene regulation Open
View article: Engineering novel CRISPRi repressors for highly efficient mammalian gene regulation
Engineering novel CRISPRi repressors for highly efficient mammalian gene regulation Open
View article: POS1257 INHIBITION OF RADIOGRAPHIC PROGRESSION WITH BIMEKIZUMAB TREATMENT OBSERVED IN BDMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AT 2 YEARS: RESULTS FROM A PHASE 3 STUDY AND ITS OPEN-LABEL EXTENSION
POS1257 INHIBITION OF RADIOGRAPHIC PROGRESSION WITH BIMEKIZUMAB TREATMENT OBSERVED IN BDMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AT 2 YEARS: RESULTS FROM A PHASE 3 STUDY AND ITS OPEN-LABEL EXTENSION Open
View article: POS0674 DIFFERENTIAL PHARMACODYNAMIC CHANGES OF CIRCULATED IMMUNE SUBSETS AFTER TREATMENT WITH ABATACEPT OR ADALIMUMAB IN PATIENTS WITH ACPA+ EARLY RA IN THE AMPLIFIED STUDY
POS0674 DIFFERENTIAL PHARMACODYNAMIC CHANGES OF CIRCULATED IMMUNE SUBSETS AFTER TREATMENT WITH ABATACEPT OR ADALIMUMAB IN PATIENTS WITH ACPA+ EARLY RA IN THE AMPLIFIED STUDY Open
View article: POS1314 ICOTROKINRA, A NOVEL TARGETED ORAL PEPTIDE, IN PATIENTS WITH PSORIATIC DISEASE: EXPLORATORY ASSESSMENTS FROM A PHASE 2 PSORIASIS STUDY INFORMING A PHASE 3 CLINICAL PROGRAM IN PSORIATIC ARTHRITIS
POS1314 ICOTROKINRA, A NOVEL TARGETED ORAL PEPTIDE, IN PATIENTS WITH PSORIATIC DISEASE: EXPLORATORY ASSESSMENTS FROM A PHASE 2 PSORIASIS STUDY INFORMING A PHASE 3 CLINICAL PROGRAM IN PSORIATIC ARTHRITIS Open
View article: P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies
P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies Open
Background/Aims Updated pooled safety data are presented to July 2023, across integrated phase 2b/3 studies of bimekizumab (BKZ) in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients. Methods Safety data are reported fo…
View article: Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update Open
View article: Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement Open
A substantial amount of literature was published on JAKi safety since 2019. A comprehensive overview of these data supports the optimal use of JAKi in patients with IMIDs, by consideration and balance of their benefits as well as risks in …
View article: Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement Open
JAKi are effective for treating IMIDs, and various compounds have recently been approved. The impact of Janus kinase (JAK) selectivity for distinct JAK-STAT pathways needs further investigation, and few data are also available on sustained…
View article: Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis
Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis Open
Objective To assess long-term tofacitinib efficacy and safety in patients with PsA with or without prior biologic DMARD (bDMARD) exposure. Methods Data were pooled post hoc from three phase 3 and one long-term extension (LTE) PsA studies a…
View article: Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis Open
Background Data on treatment switching directly from tumor necrosis factor inhibitors to tofacitinib in psoriatic arthritis (PsA) are limited. This post hoc analysis assessed efficacy and safety outcomes in patients with PsA who directly s…
View article: Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study
Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study Open
View article: Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4 Open
Objectives The aim of this article is to describe the safety and efficacy of filgotinib 200 mg (FIL200) or FIL 100 mg (FIL100) in Japanese patients with rheumatoid arthritis in a long-term extension (NCT03025308). Methods Patients who comp…
View article: Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study
Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study Open
Objective Group‐level analyses from the phase 3 DISCOVER‐2 trial of guselkumab demonstrated robust and durable improvements across psoriatic arthritis (PsA) domains. To specifically evaluate continuous disease control in individual patient…
View article: Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison Open
View article: Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison Open
NCT03895203, NCT03896581, NCT03675308, NCT03671148.
View article: Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 <scp>SELECT</scp>‐<scp>PsA</scp> 1 and 2 Randomized Controlled Trials
Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 <span>SELECT</span>‐<span>PsA</span> 1 and 2 Randomized Controlled Trials Open
Objective We explored the relationship between achievement of clinical disease control and improvements in and normative values for patient‐reported outcomes (PROs), including quality of life (QoL) measures, in patients with psoriatic arth…
View article: Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials Open
Objective This post hoc analysis assessed the effect of baseline C-reactive protein (CRP) on the efficacy and safety of tofacitinib (TOF) use in ankylosing spondylitis (AS), as well as patient-reported outcomes (PROs). Methods Phase II ( C…
View article: P112 The Impact of Filgotinib on Disease Activity Outcomes With Concomitant Pain Control in the Phase 3 FINCH Studies
P112 The Impact of Filgotinib on Disease Activity Outcomes With Concomitant Pain Control in the Phase 3 FINCH Studies Open
Background/Aims Patients with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post-hoc analysis of the FINCH studies assessed specific effects of…
View article: OA23 Time to address the challenge of difficult-to-treat psoriatic arthritis: results from an international survey
OA23 Time to address the challenge of difficult-to-treat psoriatic arthritis: results from an international survey Open
Background/Aims The term difficult-to-treat psoriatic arthritis (D2TPsA) is increasingly used to describe a small but growing number of patients who fail to respond to multiple biological disease-modifying treatments (bDMARDs). There is, h…
View article: E065 Disagreement between patient and physician global assessment over time in psoriatic arthritis: insight into treatment priorities
E065 Disagreement between patient and physician global assessment over time in psoriatic arthritis: insight into treatment priorities Open
Background/Aims The psoriatic arthritis (PsA) core domain set developed by the outcome measures in rheumatology working group includes musculoskeletal disease, fatigue, physical function, and structural damage, of which arthritis activity,…
View article: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update Open
View article: Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison Open
NCT03895203, NCT03896581, NCT04009499, NCT03158285, NCT03796858.
View article: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison Open
View article: Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study Open
Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA). Methods Post hoc analyses used…
View article: Impact of filgotinib on pain control in the phase 3 FINCH studies
Impact of filgotinib on pain control in the phase 3 FINCH studies Open
Objective This post hoc analysis of the FINCH 1–3 ( NCT02889796 , NCT02873936 and NCT02886728 ) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumato…
View article: P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study Open
Objective Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor targets select immune pathways relevant to systemic lupus erythematosus (SLE) and is approved in multiple countries for the treatment of a…
View article: A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis
A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis Open
View article: Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis Open
Objectives To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA). Method…
View article: Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies Open
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes pain and fatigue, reduces physical function, and negatively impacts health-related quality of life (HRQoL). In the phase III BE OPTIMAL and BE COMPLETE stu…